According to GlobalData’s company profile on Ipsen, Cancer treatment biomarkers was a key innovation area identified from patents. Ipsen's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20240024331A1) outlines a method for treating an INI1-negative tumor, specifically targeting rhabdoid tumors of the kidney (RTK) and atypical teratoid/rhabdoid tumors (ATRT). The method involves administering an EZH2 inhibitor to a subject in need of treatment, with the EZH2 inhibitor being orally administered to human subjects under the age of 18. The patent specifies the dosage range for the EZH2 inhibitor, ranging from about 100 mg to 3200 mg daily, with variations in dosing frequency and specific dosages mentioned in the claims.

The patent claims highlight the use of Compound (A) as the EZH2 inhibitor, along with specific dosing regimens such as 100 mg BID to 1600 mg BID. The method also includes variations in dosing, with options like 100 mg BID, 200 mg BID, 400 mg BID, 800 mg BID, or 1600 mg BID, with a specific mention of 800 mg BID. The patent further specifies that the EZH2 inhibitor can be selected from a group of inhibitors, providing flexibility in the choice of treatment. Overall, the patent outlines a method for treating INI1-negative tumors, focusing on RTK and ATRT, through the administration of EZH2 inhibitors in specific dosages and regimens.

To know more about GlobalData’s detailed insights on Ipsen, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

Be better informed